COVID 19 Associated Coagulopathy
7
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism
A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
Cardiovascular Complications in Children With COVID 19
Covid-19 Associated Coagulopathy
Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in COVID-19patients
Coagulation Disturbances in COVID-19 Septic Patients